EGFR and non-small cell lung carcinoma: A few clinical studies have been conducted to evaluate the combination of PD-1-based immunotherapy and EGFR targeted therapy in EGFR TKI-naïve and/or pretreated EGFR-mutant NSCLC patients (Table 3).